SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Solana is a high-performance Layer 1 blockchain designed for mass adoption by providing a fast, secure, and low-cost environment for decentralized applications. It distinguishes itself by scaling globally without the use of complex sharding or multiple layers, instead maintaining a single, unified ledger to avoid liquidity fragmentation. This architecture allows it to process thousands of transactions per second with sub-second finality, often at a cost of less than a penny per transaction.  The network operates on a unique hybrid model that combines Proof of Stake with an innovation called Proof of History, which functions as a decentralized clock to timestamp transactions. This system reduces the need for constant node communication, allowing the Sealevel engine to run non-conflicting smart contracts in parallel across multiple CPU cores. Further efficiency is gained through the Gulf Stream protocol, which reduces confirmation times by forwarding transactions to validators before the current block is finished.  Founded in 2017 by Anatoly Yakovenko, Solana is now supported by the Switzerland-based Solana Foundation and significant institutional investors like Andreessen Horowitz and Polychain Capital. The platform’s native token, SOL, serves as the primary currency for paying transaction fees, participating in network governance, and securing the system through staking.   Solana has also seen significant institutional adoption ranging from spot Solana ETFs to major partnerships including Visa's 2025 launch of USDC settlement on the network and the tokenization of public equity by firms like Galaxy Digital.

Solana

Solana is capturing significant community attention as market participants debate its role in tokenized asset trading and real-world financial infrastructure, with many users actively discussing the strategy of accumulating and staking tokens despite recent market volatility. Enthusiasm remains high among the community, which is highlighting Solana's potential for recovery through ecosystem developments and broader crypto market shifts.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is surging as investors speculate on a major buyout and a potential short squeeze, fueled by record short interest and anticipation for upcoming trial data. The community is actively discussing the stock's upward momentum and the intense pressure building on short sellers to cover their positions before the weekend.

ON Semiconductor Corp. engages in the provision of intelligent power and sensing solutions with a primary focus on automotive and industrial markets. It operates through the following segments: Power Solutions Group (PSG), Analog and Mixed-Signal Group (AMG), and Intelligent Sensing Group (ISG). The PSG segment offers discrete, module, and integrated semiconductor products that perform multiple application functions, including power switching, signal conditioning, and circuit protection. The AMG segment designs and develops analog, mixed-signal, power management integrated circuits, sensor interface devices, power conversion, signal chain, and voltage regulation devices. The ISG focuses on the design and development of complementary metal oxide semiconductor image sensors, image signal processors, single photon detectors, including silicon photomultipliers, single photon avalanche diode arrays, and short-wavelength infrared products, as well as actuator drivers for autofocus and image stabilization. The company was founded on July 4, 1999 and is headquartered in Scottsdale, AZ.

ON Semiconductor Corp.

ON Semiconductor is facing significant downward pressure following an all-stock acquisition of Synaptics that has triggered widespread investor concerns over shareholder dilution. While some community members highlight the long-term strategic potential in Edge AI and physical AI infrastructure, current sentiment is dominated by anxiety regarding the deal structure, leading many to warn of a volatile near-term outlook.

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain as well as the Onyx Goliath Blockchain. XCN is also used as an ERC-20 token for Staking and Governance.

Onyxcoin

Onyxcoin (XCN) is currently trending amid significant community anticipation surrounding the upcoming Goliath mainnet launch and related speculative activity. Traders are actively debating whether the project will deliver on its institutional infrastructure promises or if recent price action is merely another cyclical pattern of accumulation and volatility.

Aave is a decentralized money market protocol where users can lend and borrow cryptocurrency across 20 different assets as collateral. The protocol has a native token called AAVE, which is also a governance token that lets the community decide the direction of the protocol in a collective manner. Lenders can&nbsp;earn interest by providing liquidity to the market, while borrowers can borrow by collateralizing their cryptoassets to take out loans from the liquidity pools.

AAVE

AAVE is trending following strong momentum and market optimism, fueled by the protocol's expansion into new networks and ongoing community discussions regarding its potential for long-term growth. Investors are focused on Aave's dominance as a leading DeFi lending platform and the anticipated impact of its V4 protocol upgrades.

Polestar Automotive Holding UK Plc is the Swedish electric performance car brand that engages in the research, development, marketing, commercialization, and sales of battery electric vehicles and related technology solutions. It offers Polestar 2 (PS2), a premium fast-back sedan, the Polestar 3 (PS3), a luxury aero sport-utility vehicle, the Polestar 4 (PS4), a premium sport utility vehicle, the Polestar 5 (PS5), a luxury sport grand-touring sedan, and the Polestar 6 (PS6), a luxury roadster. The company was founded on September 15, 2021 and is headquartered in Gothenburg, Sweden.

Polestar Automotive Holding UK PLC - ADR Class A

Polestar Automotive Holding UK PLC

Polestar is facing significant downward pressure and intense community debate following a federal decision to block its new vehicle sales in the U.S. starting in 2027, with many investors debating whether the company should retreat to prioritize profitability in European markets or fight the ruling.

Fartcoin is a meme-driven cryptocurrency where users can submit their best fart jokes or memes to earn initial tokens. Each transaction triggers a hilarious 'Gas Fee' effect, complete with a digital fart sound for maximum comedic impact.

Fartcoin

FARTCOIN is at the center of a heated debate within the crypto community, with supporters highlighting its established meme status and liquidity, while detractors label it as a speculative "shitcoin" prone to extreme volatility. Much of the active discussion involves high-conviction traders comparing it to other community-driven projects like UPDOG, creating a narrative that centers on cross-holding patterns and the intense, often humorous, speculation surrounding the token's long-term utility.

TokenOS is the world’s most advanced AI-powered Web3 development platform, designed to turn natural language prompts into fully functional, production-ready blockchain applications. From simple tokens and memecoins to complex DeFi protocols, TokenOS automates the creation, deployment, and auditing of smart contracts and dApps with enterprise-grade reliability. By combining advanced language models with blockchain infrastructure, TokenOS removes the barriers of technical expertise, making Web3 development accessible to everyone. With instant deployment, built-in security best practices, and cross-chain support on the roadmap, TokenOS empowers entrepreneurs, developers, and creators to launch tokenized businesses and decentralized applications in seconds.

TokenOS AI

TokenOS AI is trending as investors highlight the project's v4 launch and a revenue-sharing model that distributes decentralized compute earnings to node runners and stakers. The community is focused on the project's low market cap and the high percentage of supply locked in long-term staking, which many view as a bullish catalyst for future price action.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is currently trending due to the robust adoption of its oral Wegovy pill, which has surpassed three million prescriptions shortly after launch, signaling strong market expansion despite intense competition from Eli Lilly. The community remains deeply divided, with bulls highlighting the company's attractive valuation and potential for long-term growth as a defensive healthcare play, while bears point to clinical pipeline setbacks and concerns over margin pressure in an increasingly crowded weight-loss market.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals is attracting intense investor scrutiny as trading volume surges following recent significant insider share acquisitions and a new clinical data release, fueling strong community speculation regarding a potential buyout or strategic pivot. While retail sentiment remains optimistic due to the CEO's aggressive accumulation of shares, some participants express frustration over persistent share price volatility and the lack of immediate, high-impact PR catalysts.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Wave Life Sciences (WVE) Upgraded to Buy: Here's Why

Wave Life Sciences (WVE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Strength Seen in Intellia Therapeutics (NTLA): Can Its 23.2% Jump Turn into More Strength?

Intellia Therapeutics (NTLA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

This $5.5 Million Exit Raises Questions After Wave Life Sciences' Rough First Quarter

This $5.5 Million Exit Raises Questions After Wave Life Sciences' Rough First Quarter...

Wave Life Sciences Supports AlphaDetect to Accelerate Detection of Alpha-1

Wave Life Sciences Supports AlphaDetect to Accelerate Detection of Alpha-1 Wave Life Sciences Supports AlphaDetect to Accelerate Detection of Alpha-1 PR Newswire DURHAM, N.C., May 19, 2026 The...

WVE Stock Edges Up After Positive Early Data For Rare Disease Drug  

Equity

The Cambridge-based biotech said its drug WVE-006 produced promising effects in patients with the most severe form of alpha-1 antitrypsin deficiency.

HC Wainwright Expects Higher Earnings for WAVE Life Sciences

WAVE Life Sciences Ltd. (NASDAQ:WVE - Free Report) - Equities research analysts at HC Wainwright upped their Q2 2026 earnings estimates for WAVE Life Sciences in a report issued on Wednesday, April 29th. HC Wainwright analyst A. Fein now expects that the company will post earnings per share of ($0.3...

Pictet Asset Management Holding SA Purchases 790,175 Shares of WAVE Life Sciences Ltd. $WVE

Pictet Asset Management Holding SA boosted its holdings in shares of WAVE Life Sciences Ltd. (NASDAQ:WVE - Free Report) by 5,024.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 805...

WAVE Life Sciences (NASDAQ:WVE) Upgraded to "Hold" at Wall Street Zen

Wall Street Zen raised shares of WAVE Life Sciences from a "strong sell" rating to a "hold" rating in a research report on Saturday...

WAVE Life Sciences Ltd. (NASDAQ:WVE) Given Consensus Rating of "Moderate Buy" by Analysts

WAVE Life Sciences Ltd. (NASDAQ:WVE - Get Free Report) has been given a consensus rating of "Moderate Buy" by the fifteen research firms that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation and fourteen have i...

WAVE Life Sciences (NASDAQ:WVE) Given New $43.00 Price Target at Canaccord Genuity Group

Canaccord Genuity Group dropped their price target on shares of WAVE Life Sciences from $52.00 to $43.00 and set a "buy" rating on the stock in a research note on Thursday...

Wave Life Sciences Ltd. is a clinical-stage biotechnology company, which focuses on developing its proprietary RNA medicines platform and PRISM. It develops and commercializes a pipeline of RNA medicines across a variety of therapeutic areas. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Singapore.

Wave Life Sciences Ltd.

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

WVEWave Life Sciences Ltd

Fundamentals

Latest WVE News